Sarcopenia, loss of muscle mass and strength, is common in older-adults and it is a major clinical concern in public health globally as it is associated with increased risk of osteoporosis, falls, fractures, disability, impaired capacity to perform activities of daily living and poor quality of life.

The main aim of the Sarcopenia-Clinical Program is to identify novel pharmacological and non-pharmacological (exercise and diet) interventions to prevent, manage and treat sarcopenia, and its associated comorbidities and improve the quality of life of people with sarcopenia. 

The program brings together a wide variety of disciplines and expertise including exercise science, physiology, medicine, cardiology and endocrinology.

This research focuses on:

  • Bone-muscle cross talk: effects on sarcopenia
  • Uncovering the Interaction between Circulating Osteoprogenitor (COP) Cells and Osteocalcin in Older-Adults with Osteosarcopenia: Effects of Exercise
  • Novel drug treatment to manage/treat sarcopenia and its associated comorbidities
  • Sarcopenic obesity, falls and fracture risk
  • Osteogenic exercise for obese older adults
  • Falls prevention for older adults
  • Virtual reality balance training
  • Whole body vibration training
  • Effects of vitamin D on muscle, balance and bone health in obese older adults

Program Members

Itamar Levinger

Program Director

Dr Jujio Kuang

Project Director

Scroll to Top